{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:16:48Z","timestamp":1781713008684,"version":"3.54.5"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>As compared to controlled or uncontrolled hypertension, resistant hypertension in patients with chronic kidney disease (CKD) poses a significantly increased healthcare burden due to greater target end-organ damage including cardiovascular disease and CKD progression. Patients with CKD have two to three times higher risk of developing resistant hypertension. True resistant hypertension needs to be distinguished from apparent treatment resistant hypertension (aTRH); however, it is usually not possible in epidemiological studies. Moreover, impact of contemporary guidelines changes in the target blood pressure (BP) goal to less than 130\/80\u200ammHg remains to be determined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Up to half of patients with CKD meet aTRH criteria using 2017\u200aACC\/AHA target BP less than 130\/80\u200ammHg. Excess sodium retention in extracellular and tissue compartment remains the cornerstone cause of resistance to the treatment in CKD. Maximizing and optimizing the diuretic regimen in addition to dietary sodium restriction plays a critical role in these patients. Management requires a trustworthy provider-patient relationship facilitating identification and intervention for the barriers restricting the uptake of lifestyle modifications and medications. Recently, renal denervation has been approved and many other novel agents are on the horizon for treatment of true resistant hypertension associated with CKD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>This review discusses the latest in the pathophysiology, definition, identification and treatment strategies of resistant hypertension in individuals with CKD. Further investigations are required to identify the prevalence, future implication and treatment outcome data for true resistant hypertension associated with CKD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mnh.0000000000001002","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T06:00:10Z","timestamp":1715320810000},"page":"465-473","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Revisiting resistant hypertension in kidney disease"],"prefix":"10.1097","volume":"33","author":[{"given":"Shweta","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","article-title":"Hypertension in CKD: core curriculum 2019","volume":"74","author":"Ku","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R4-20250729","first-page":"385","article-title":"Intensive BP control in patients with CKD and risk for adverse outcomes","volume":"34","author":"Ku","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7326\/M14-1539","article-title":"Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force","volume":"162","author":"Piper","year":"2015","journal-title":"Ann Intern Med"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2215\/CJN.05391008","article-title":"Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis","volume":"4","author":"Bangash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","article-title":"Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network","volume":"62","author":"Egan","year":"2013","journal-title":"Hypertension"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1080\/10641963.2018.1433193","article-title":"Resistant and undertreated hypertension in patients with chronic kidney disease: data from the PATRIOTIC survey","volume":"40","author":"Zheng","year":"2018","journal-title":"Clin Exp Hypertens"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","article-title":"Resistant hypertension? Assessment of adherence by toxicological urine analysis","volume":"31","author":"Jung","year":"2013","journal-title":"J Hypertens"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2215\/CJN.00550113","article-title":"Prevalence of apparent treatment-resistant hypertension among individuals with CKD","volume":"8","author":"Tanner","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2215\/CJN.04110422","article-title":"Prevalence of apparent treatment-resistant hypertension in chronic kidney disease in two large US healthcare systems","volume":"17","author":"An","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-20250729","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.0000000000000315","article-title":"Resistant hypertension in dialysis: epidemiology, diagnosis, and management","author":"Georgianos","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00041552-199305000-00001","article-title":"A method for distinguishing salt-sensitive from nonsalt-sensitive forms of human and experimental hypertension","volume":"2","author":"Kimura","year":"1993","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R15-20250729","first-page":"49","article-title":"Roles of the kidneys and fluid volumes in arterial pressure regulation and hypertension","volume":"32","author":"Guyton","year":"1989","journal-title":"Chin J Physiol"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"F729","DOI":"10.1152\/ajprenal.00407.2020","article-title":"Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms","volume":"319","author":"Bovee","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1093\/ndt\/14.11.2599","article-title":"Can antihypertensive medications control BP in haemodialysis patients: yes or no?","volume":"14","author":"Scribner","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the Chronic Renal Insufficiency Cohort Study","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/HJH.0b013e328353634e","article-title":"Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs","volume":"30","author":"de la Sierra","year":"2012","journal-title":"J Hypertens"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/cvr\/cvaa336","article-title":"Obesity, kidney dysfunction, and inflammation: interactions in hypertension","volume":"117","author":"Hall","year":"2021","journal-title":"Cardiovasc Res"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.2013030285","article-title":"A randomized trial of dietary sodium restriction in CKD","volume":"24","author":"McMahon","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2215\/CJN.01120216","article-title":"A randomized crossover trial of dietary sodium restriction in stage 3-4 CKD","volume":"12","author":"Saran","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41440-020-0428-y","article-title":"Sodium-induced inflammation-an invisible player in resistant hypertension","volume":"43","author":"Targonski","year":"2020","journal-title":"Hypertens Res"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0272-6386(99)70413-0","article-title":"Mechanism of erythropoietin-induced hypertension","volume":"33","author":"Vaziri","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/ki.1993.100","article-title":"Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure","volume":"43","author":"Raine","year":"1993","journal-title":"Kidney Int"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1681\/ASN.2004070582","article-title":"Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide","volume":"16","author":"Passauer","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrneph.2011.31","article-title":"The role of asymmetric and symmetric dimethylarginines in renal disease","volume":"7","author":"Schwedhelm","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/00004872-200111000-00018","article-title":"High prevalence of cardiac and extracardiac target organ damage in refractory hypertension","volume":"19","author":"Cuspidi","year":"2001","journal-title":"J Hypertens"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2015.142","article-title":"Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension","volume":"88","author":"Sim","year":"2015","journal-title":"Kidney Int"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Group","year":"2015","journal-title":"N Engl J Med"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1053\/j.ajkd.2019.08.030","article-title":"Blood pressure measurement: a KDOQI perspective","volume":"75","author":"Drawz","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000321688","article-title":"Adherence to antihypertensive agents and blood pressure control in chronic kidney disease","volume":"32","author":"Schmitt","year":"2010","journal-title":"Am J Nephrol"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjmed.2019.04.040","article-title":"Trends in dietary sodium intake in the United States and the impact of USDA Guidelines: NHANES 1999\u20132016","volume":"132","author":"Brouillard","year":"2019","journal-title":"Am J Med"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1161\/CIRCULATIONAHA.116.024446","article-title":"Sources of sodium in US adults from 3 geographic regions","volume":"135","author":"Harnack","year":"2017","journal-title":"Circulation"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1056\/NEJMoa0907355","article-title":"Projected effect of dietary salt reductions on future cardiovascular disease","volume":"362","author":"Bibbins-Domingo","year":"2010","journal-title":"N Engl J Med"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa2105675","article-title":"Effect of salt substitution on cardiovascular events and death","volume":"385","author":"Neal","year":"2021","journal-title":"N Engl J Med"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.3390\/nu13082678","article-title":"Randomized trial on the effects of dietary potassium on blood pressure and serum potassium levels in adults with chronic kidney disease","volume":"13","author":"Turban","year":"2021","journal-title":"Nutrients"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/CIRCULATIONAHA.121.055329","article-title":"Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial","volume":"144","author":"Blumenthal","year":"2021","journal-title":"Circulation"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/01.CIR.23.2.200","article-title":"Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics","volume":"23","author":"Reubi","year":"1961","journal-title":"Circulation"},{"key":"R41-20250729","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1751-7176.2007.tb00009.x","article-title":"Maximizing diuretic therapy in resistant hypertension","volume":"9","author":"Handler","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R43-20250729","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1751-7176.2011.00564.x","article-title":"A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease","volume":"14","author":"Dussol","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R44-20250729","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"R45-20250729","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"R46-20250729","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.kint.2019.02.018","article-title":"The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial","volume":"95","author":"Loutradis","year":"2019","journal-title":"Kidney Int"},{"key":"R47-20250729","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1053\/j.ajkd.2012.12.017","article-title":"Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial","volume":"61","author":"Hur","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R48-20250729","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1681\/ASN.2017010040","article-title":"Acute declines in renal function during intensive BP lowering: implications for future ESRD risk","volume":"28","author":"Ku","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R49-20250729","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1681\/ASN.2018121261","article-title":"Implications of early decline in eGFR due to intensive BP control for cardiovascular outcomes in SPRINT","volume":"30","author":"Beddhu","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"(3S)","key":"R50-20250729","first-page":"S1","article-title":"Kidney Disease: Improving Global Outcomes Blood Pressure Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"R51-20250729","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40620-021-00966-7","article-title":"Insights on safety and efficacy of renal artery denervation for uncontrolled-resistant hypertension in a high risk population with chronic kidney disease: first Italian real-world experience","volume":"34","author":"Marin","year":"2021","journal-title":"J Nephrol"},{"key":"R52-20250729","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/HJH.0000000000000556","article-title":"Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension","volume":"33","author":"Ott","year":"2015","journal-title":"J Hypertens"},{"key":"R53-20250729","article-title":"SCAI Position Statement on Renal Denervation for Hypertension: patient selection, operator competence, training and techniques, and organizational recommendations","volume":"2","author":"Rajesh","year":"2023","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"R54-20250729","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"R55-20250729","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"R56-20250729","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"}],"container-title":["Current Opinion in Nephrology &amp; Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNH.0000000000001002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T23:01:51Z","timestamp":1753830111000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNH.0000000000001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mnh.0000000000001002","relation":{},"ISSN":["1062-4821","1473-6543"],"issn-type":[{"value":"1062-4821","type":"print"},{"value":"1473-6543","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}